The effects of aspirin and fish oil consumption on lysophosphatidylcholines and lysophosphatidic acids and their correlates with platelet aggregation in adults with diabetes mellitus

Prostaglandins Leukot Essent Fatty Acids. Feb-Mar 2014;90(2-3):61-8. doi: 10.1016/j.plefa.2013.12.004. Epub 2013 Dec 18.

Abstract

Many diabetics are insensitive to aspirin's platelet anti-aggregation effects. The influence of co-administration of aspirin and fish oil (FO) on plasma lysophospholipids in subjects with diabetes is poorly characterized. Thirty adults with type 2 diabetes mellitus were treated with aspirin (81mg/day) for seven days, then with FO (4g/day) for 28 days, then in combination for another seven days. Lysophospholipids and platelet measures were determined after acute (4h) and chronic (7 days) ingestion of aspirin, FO, or both in combination. FO ingestion reduced all lysophosphatidic acid (LPA) concentrations, while EPA (20:5n-3) and DHA (22:6n-3) lysophosphatidylcholine (LPC) concentrations significantly increased after FO alone and in combination with aspirin. In vitro arachidonic acid-induced platelet aggregation was most strongly correlated with palmitoleic (16:1) and oleic (18:1) LPA and LPC concentrations at all time points. The ingestion of these agents may reduce cardiovascular disease risk in diabetic adults, with a disrupted lipid milieu, via lysolipid mediated mechanisms.

Trial registration: ClinicalTrials.gov NCT01181882.

Keywords: Aspirin; Docosahexaenoic acid; Eicosapentaenoic acid; Lysophosphatidic acid; Lysophosphatidylcholine; Omega-3 fatty acids; Platelet function.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Aspirin / pharmacology*
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Eating / physiology
  • Feeding Behavior
  • Female
  • Fish Oils / pharmacology*
  • Fishes
  • Humans
  • Lysophosphatidylcholines / blood*
  • Lysophospholipids / blood*
  • Male
  • Middle Aged
  • Platelet Aggregation / drug effects*

Substances

  • Fish Oils
  • Lysophosphatidylcholines
  • Lysophospholipids
  • Aspirin

Associated data

  • ClinicalTrials.gov/NCT01181882